^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    apalutamide

    i
    Other names: ARN 509, JNJ56021927, JNJ-927, JNJ-56021927, ARN-509, ARN509, JNJ 56021927, JNJ927, JNJ 927
    Company:
    Generic mfg.
    Drug class:
    Androgen receptor antagonist
    Related drugs:
    1d
    Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (clinicaltrials.gov)
    P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • apalutamide • triptorelin • goserelin acetate • AiRuiEn (rezvilutamide)
    6d
    Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=93, Completed, Institut Paoli-Calmettes | Unknown status --> Completed | N=206 --> 93
    Trial completion • Enrollment change
    |
    apalutamide
    7d
    PROTEUS: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (clinicaltrials.gov)
    P3, N=2517, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial primary completion date
    |
    apalutamide
    11d
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Terminated, M.D. Anderson Cancer Center | Trial completion date: Apr 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)
    14d
    Behavioral Alterations in Male Zebrafish After Administration of Androgen Receptor Blockers and an Activator. (PubMed, Biology (Basel))
    Enzalutamide (ENZ) and apalutamide (APA) are two second-generation androgen receptor inhibitors (SGARIs) that have been primarily used in the treatment of prostate cancer. In conclusion, functional modulation of androgen receptor signaling leads to significant alterations in male zebrafish behavior, particularly affecting fear responses, aggression, and anxiety-related behaviors. We believe that these findings could contribute to a deeper understanding of the relationship between androgens and behaviors in vertebrates, especially zebrafish.
    Journal
    |
    AR (Androgen receptor)
    |
    Xtandi (enzalutamide) • apalutamide
    14d
    Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | N=34 --> 8 | Trial completion date: Dec 2027 --> Apr 2026 | Trial primary completion date: Mar 2027 --> Jul 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    apalutamide • Simponi (golimumab)
    21d
    DynaMO: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • apalutamide
    22d
    OBSAPA: A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France (clinicaltrials.gov)
    P=N/A, N=270, Recruiting, Janssen Cilag S.A.S.
    New trial
    |
    apalutamide
    27d
    Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Provenge (sipuleucel-T)
    29d
    Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. (PubMed, Case Rep Oncol Med)
    A 75-year-old man with mHSPC was treated with Apa and leuprorelin. Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.
    Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    apalutamide • cyclosporine • leuprolide acetate for depot suspension
    30d
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=183, Active, not recruiting, Janssen Research & Development, LLC | N=50 --> 183
    Enrollment change • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    1m
    PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC. (clinicaltrials.gov)
    P=N/A, N=168, Completed, First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    docetaxel • Xtandi (enzalutamide) • apalutamide